India Ratifies Nagoya Protocol On Biodiversity Access And Benefit-Sharing 05/10/2012 by Intellectual Property Watch Leave a Comment The Union Cabinet of India has approved ratification of the Nagoya Protocol on Access and Benefit-Sharing, a measure that provides a tool against biopiracy. The 4 October action comes on the eve of the 11th Conference of Parties to the UN Convention on Biological Diversity (CBD).
Q&A With Newly Appointed KIPO Commissioner 24/09/2012 by William New, Intellectual Property Watch 1 Comment Ho-Won Kim, the newly appointed commissioner of the Korean Intellectual Property Office (KIPO), discussed his views on KIPO’s major policies in a recent exchange with Intellectual Property Watch. He explained the directions KIPO will take on international cooperation, examination pendency periods, and other issues, such as what the international dispute between Samsung Electronics and Apple means for companies worldwide.
India: Balancing Public And Private Interests In The Intellectual Property Regime 18/09/2012 by Patralekha Chatterjee for Intellectual Property Watch 5 Comments NEW DELHI – In this month, there have been two court orders in India that underscore the complexities underlying the country’s intellectual property regime. Last Friday (14 September), the Chennai-based Intellectual Property Appellate Board (IPAB) which is responsible for hearing appeals on patent applications, rejected a petition by German pharma major Bayer AG, seeking a stay on an order of India’s Controller of Patents granting a compulsory licence (CL) to Indian generic drug maker Natco Pharma Limited, for a drug used to treat liver and kidney cancer.
Novartis Challenge To India Patent Law Put Off To 11 September 22/08/2012 by Intellectual Property Watch Leave a Comment The Supreme Court of India today did not get to an agenda item involving a challenge to India’s patent law by Swiss pharmaceutical company Novartis, and it is now scheduled to come up on 11 September. The case is considered to have potential widespread impact on the production of lower priced generic medicines.
MSF: India’s Bayer-Natco Compulsory Licence Case Set For 3 Sept. 21/08/2012 by Intellectual Property Watch 1 Comment A hearing in a case involving a challenge by Bayer pharmaceutical company of India’s compulsory licence aimed at making a cancer drug more affordable is moved to 3 September, public health advocacy group Médecins Sans Frontières (MSF) announced today.
A Look At India’s Key Pharmaceutical Patent Case 07/08/2012 by Intellectual Property Watch Leave a Comment This month, the Indian Supreme Court will hear final arguments in a challenge by the pharmaceutical company Novartis against the Indian Patent Office’s rejection of a patent for the leukemia drug, Glivec. The Court’s ruling will have profound implications for pharmaceutical patenting in India, and more generally how countries with newly introduced pharmaceutical patent regimes […]
Novartis’ Indian Patent Law Challenge Postponed Again 06/07/2012 by Intellectual Property Watch Leave a Comment The Supreme Court of India has postponed hearing final arguments in a key challenge to India’s patent law brought by Swiss pharmaceutical company Novartis.
Asian Governments Plan To Better Use TRIPS Flexibilities For Health 01/06/2012 by William New, Intellectual Property Watch 2 Comments International trade rules related to intellectual property rights enshrine the notion that there may be cases where exceptions to IP rights are needed by governments, such as sovereign decisions on a nation’s public health. Using those flexibilities could save millions of lives but may mean taking a tough stance in free trade negotiations with bigger trading partners, concluded a meeting of Asian stakeholders this week.
Compulsory Licences Positive For The South, With Conditions, Study Finds 31/05/2012 by Catherine Saez, Intellectual Property Watch Leave a Comment Compulsory licences can provide an efficient way to decrease prices of drugs in developing countries but the conditions of issuance of a licence influence the benefits countries can derive from them, particularly if the countries have a technology gap, according to an economic model presented this week at the World Intellectual Property Organization.
US, China To Hold Landmark Intellectual Property Adjudication Meeting 24/05/2012 by Maricel Estavillo for Intellectual Property Watch Leave a Comment The United States and China will hold early next week what is becoming the largest bilateral programme between their courts in the area of intellectual property adjudication. Set to gather more than a thousand participants, the discussions will largely revolve around patent litigation, according to a top US judge.